 |
市場調查報告書
商品編碼
2045149
腫瘤浸潤淋巴細胞療法（TIL療法）市場：策略性洞察與預測（2026-2031年）Tumor-Infiltrating Lymphocyte (TIL) Therapy Market - Strategic Insights and Forecasts (2026-2031) |
||||||
腫瘤浸潤淋巴細胞 (TIL) 療法市場預計將從 2026 年的 3.3251 億美元成長到 2031 年的 5.50494 億美元，複合年成長率為 10.6%。
隨著醫療系統擴大採用先進的免疫療法來治療固體癌和難治性癌症，全球腫瘤浸潤淋巴細胞（TIL）療法市場正在顯著擴張。 TIL療法是一種過繼性細胞療法，它利用患者腫瘤微環境中天然存在的免疫細胞。這些淋巴細胞從腫瘤組織中分離出來，在體外培養，然後重新輸注回患者體內，以刺激靶向抗腫瘤免疫反應。對於對傳統治療方法或查核點抑制劑反應有限的晚期癌症患者，TIL療法正逐漸成為備受關注的治療方法。
全球癌症負擔日益加重，仍是推動市場成長要素之一。隨著黑色素瘤、子宮頸癌、肺癌、大腸癌、卵巢癌和頭頸癌發生率的上升，人們對能夠改善治療效果的創新免疫療法的需求日益成長。傳統的治療方法，例如化療和放射線治療，常常面臨全身毒性、腫瘤抗藥性和疾病復發等限制。 TIL療法因其能夠提供個人化、標靶性、免疫介導的抗癌作用，並具有持續臨床療效的潛力，而正被越來越多的機構所採用。
個人化醫療和精準腫瘤學的廣泛應用顯著推動了市場成長。由於TIL療法利用患者自身來源的免疫細胞，因此能夠根據患者腫瘤的生物學特徵和免疫譜制定高度個人化的治療策略。整合基因組分析、生物標記分析和分子診斷的精準醫療方法進一步強化了細胞免疫療法在腫瘤治療方案製定中的作用。
細胞增殖技術、腫瘤分析、基因編輯和細胞生產平台等領域的技術進步正在改變TIL治療市場。自動化生產系統、改進的淋巴細胞分離方法和最佳化的細胞培養技術提高了生產效率和擴充性。研究人員正持續探索基因修飾的TIL、合併免疫療法以及新一代細胞工程技術，以增強治療效果和延長療效持續時間。
此外，製藥和生物技術公司加大對腫瘤免疫學研究和過繼性細胞療法開發的投資，也對市場產生了積極影響。各公司正在擴大針對固體癌浸潤淋巴細胞（TIL）療法以及聯合治療查核點抑制劑、細胞激素療法和標靶治療的臨床試驗計畫。生物技術公司、癌症研究機構和醫療服務提供者之間的策略合作正在加速個人化免疫療法解決方案的創新。
監管支持的擴大和公眾對細胞免疫療法認知度的提高進一步推動了市場成長。監管機構正加速核准流程和孤兒藥認定等方式，大力支持先進免疫療法的研發。醫療機構和腫瘤中心也在增加對專業細胞治療基礎設施和認證治療設施的投資，以支持其在臨床實踐中的更廣泛應用。
北美目前在腫瘤浸潤淋巴細胞（TIL）療法市場佔據主導地位，這得益於其先進的生物技術基礎設施、強大的腫瘤學研究能力以及對免疫療法創新的大量投資。歐洲也是一個龐大的市場，這得益於精準醫療計畫的持續推進和癌症研究計畫的拓展。亞太地區預計將經歷快速成長，這主要歸因於醫療保健成本的上升、癌症負擔的加重以及中國、日本、韓國和印度等國家在生物技術領域投資的不斷增加。
儘管預計市場將保持強勁成長，但該市場也面臨許多挑戰，例如治療成本高昂、生產製造複雜、規模化生產受限以及治療相關不利事件。然而，自動化細胞製造、基因組醫學和聯合免疫療法策略的不斷進步有望為腫瘤浸潤淋巴細胞療法（TIL療法）市場創造長期成長機會。
市場促進因素
固體癌發生率增加
全球固態腫瘤發生率的不斷上升是腫瘤浸潤淋巴細胞（TIL）療法市場的主要促進因素之一。隨著黑色素瘤、子宮頸癌、肺癌、大腸直腸癌和卵巢癌病例的增加，對能夠提高患者存活率的先進免疫療法解決方案的需求日益成長。
TIL療法在晚期或難治性癌症患者中展現出令人鼓舞的臨床療效，尤其是在黑色素瘤和子宮頸癌方面。越來越多的臨床證據支持其能夠持續緩解症狀，這正在加速醫生對該療法的應用和臨床研究的發展。
擴大個人化免疫療法的應用
人們對個人化醫療和標靶腫瘤治療日益成長的興趣正在顯著推動市場成長。 TIL療法利用患者來源的免疫細胞進行開發，從而實現針對腫瘤特異性免疫反應的高度個人化治療方案。
醫療機構正擴大採用個人化免疫療法來提高治療準確性、降低復發風險並改善長期治療效果。
細胞增殖和製造技術的進步
細胞分離、淋巴細胞增殖、自動化生產和細胞工程技術的持續創新正在對市場產生積極影響。生產平台的改進提高了擴充性，降低了污染風險，並提高了生產的一致性。
自動化、封閉式系統製造技術有望縮短生產時間，並改善整個醫療保健系統更廣泛地獲得 TIL 療法的機會。
增加免疫腫瘤學研究的投資
製藥公司、生物技術公司和研究機構正在大幅增加對TIL療法臨床試驗和免疫腫瘤學研究的投資。研究人員正在評估TIL療法在多種固體癌適應症和聯合治療策略中的應用。
使用查核點抑制劑、細胞激素療法和標靶治療的聯合治療已顯示出良好的臨床潛力，並正在擴大未來的治療機會。
擴大對細胞療法的監管支持
監管機構正透過加速審查計畫、孤兒藥認定和再生醫學框架，日益支持先進細胞療法的發展。
過繼性細胞療法監管核准的增加以及腫瘤基礎設施醫療保健投資的擴大，正在改善長期市場成長前景。
市場限制因素
TIL療法高成本
腫瘤浸潤淋巴細胞（TIL）療法市場面臨的主要限制因素之一是治療和個人化生產過程的高成本。 TIL療法涉及腫瘤組織採集、淋巴細胞分離、細胞增殖和回輸等步驟，這些都需要專門的基礎設施和技術專長。
高昂的治療費用可能會限制患者獲得治療的機會，並造成報銷方面的挑戰，尤其是在新興的醫療保健市場。
複雜且耗時的製造過程
TIL療法的生產涉及多個複雜流程，包括手術切除腫瘤、體外淋巴細胞增殖、品管檢測和回輸。生產過程耗時較長，且需要大量資源。
調整個人化製造流程並保持一致的製造品質可以限制其在臨床環境中的可擴展性和更廣泛的應用。
治療相關不利事件
TIL療法可能涉及與淋巴細胞清除化療、細胞激素給藥和免疫活化相關的不利事件。患者可能出現細胞激素相關毒性、免疫併發症和治療相關副作用，需要專業人員監測。
不利事件的處理通常需要在配備有強化支持治療設施的認證癌症中心進行。
商業化程度有限，基礎建設也較為匱乏。
目前，TIL療法僅在少數配備專業細胞治療基礎設施和生產能力的醫療機構提供。由於治療機構數量有限，某些地區的患者可能難以獲得該療法。
在醫療保健系統中，可能需要對細胞處理設施、熟練人員和監管合規系統進行大量投資，以支援更廣泛的應用。
對技術和細分市場的洞察
腫瘤浸潤淋巴細胞（TIL）療法市場按治療方法類型、癌症適應症、終端用戶和地區進行細分。治療方法類型包括自體TIL療法、基因修飾TIL療法和合併TIL療法。由於其成熟的臨床開發記錄和在黑色素瘤治療中日益廣泛的應用，自體TIL療法目前佔據市場主導地位。
由於基因編輯技術的進步以及提高治療效果持續時間和抗腫瘤活性的努力，人們對基因修飾的TIL療法的興趣也日益成長。
根據癌症適應症，該市場涵蓋黑色素瘤、子宮頸癌、肺癌、大腸癌、卵巢癌以及頭頸癌。目前，黑色素瘤佔最大的市場佔有率，這主要歸功於強力的臨床證據支持TIL療法對進行性黑色素瘤患者的療效。
此外，隨著臨床試驗的活性化和人們對固體癌免疫療法的興趣日益濃厚，子宮頸癌和肺癌正在成為新的應用領域。
按最終用戶分類，市場包括醫院、癌症治療中心、學術和研究機構以及專科癌症診所。由於實施TIL療法涉及複雜的臨床管理和基礎設施要求，目前醫院和專科癌症治療中心佔據了市場的大部分佔有率。
此外，學術和研究機構也是主要貢獻者，因為它們參與免疫療法臨床試驗和轉化腫瘤學研究的程度越來越高。
從區域來看，北美市場佔據主導地位，這得益於其先進的生物技術生態系統、強大的腫瘤研究基礎設施以及對免疫療法創新的大量醫療保健投資。歐洲市場持續保持強勁成長，主要得益於精準醫療計畫的推進和腫瘤臨床研究的拓展。亞太地區預計將快速擴張，這主要得益於醫療保健基礎設施的改善、癌症患者數量的增加以及對生物技術投資的增加。
競爭與策略展望
腫瘤浸潤淋巴細胞（TIL）療法市場競爭激烈，生物技術公司、免疫療法開發商和腫瘤研究機構都參與其中。主要市場參與企業包括Iovance Biotherapeutics, Inc.、Achilles Therapeutics plc、Instil Bio, Inc.、Obsidian Therapeutics, Inc.、Turnstone Biologics Corp.、Genocea Biosciences, Inc.、BioNTech SE、Merck & Co., Inc.、Bristol Myers Squibb Company和 Ltd Hyers。
領導企業正日益關注下一代TIL療法、自動化生產平台和聯合免疫療法，以鞏固其市場地位。基因編輯技術、人工智慧驅動的生物標記發現和先進細胞工程領域的投資正在全行業加速成長。
Iovance Biotherapeutics 透過擴大其 lifileucel 的臨床開發和 TIL 生產能力，持續保持著強勁的市場地位。生技公司正擴大評估 TIL 療法與查核點抑制劑和標靶治療合併應用，以提高固體癌的治療效果。
生技公司、製藥企業和癌症研究機構之間的策略合作正在加速過繼性細胞療法的創新發展。此外，各公司正增加對分散式生產平台和自動化生產系統的投資，以提高規模化生產能力和病患可近性。
市場日益關注延長治療效果持續時間、簡化生產流程、拓展應用範圍至多種固體癌適應症。能夠提高生產效率、改善臨床療效和擴大治療可近性的公司有望增強其長期市場競爭力。
結論
由於癌症發病率上升、個人化免疫療法的日益普及以及細胞療法技術的不斷進步，全球腫瘤浸潤淋巴細胞 (TIL) 療法市場預計將經歷強勁成長。
TIL療法利用患者自身來源的淋巴球，實現個人化、標靶的免疫介導抗癌反應，進而改變固體癌的治療。對腫瘤免疫學研究、基因組醫學和先進細胞製造技術的投資不斷增加，進一步推動了市場擴張。
自動化細胞處理、基因編輯、生物標記分析和聯合免疫療法策略等方面的技術進步顯著提升了治療方法創新性和臨床應用潛力。然而，高昂的治療成本、複雜的生產製造、治療相關不利事件以及有限的治療基礎設施等挑戰仍然阻礙這些技術在市場上的廣泛應用。
儘管有這些局限性，但過繼性細胞療法、個人化腫瘤學和精準免疫療法的持續創新有望為腫瘤浸潤淋巴細胞療法（TIL 療法）市場創造重要的長期成長機會。
本報告的主要益處
- 深入分析：對各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業領域進行詳細的市場洞察。
- 競爭格局：了解主要參與者的策略舉措，並確定最佳的市場進入方式。
- 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
- 實用建議：我們支援制定策略決策以開發新的收入來源。
- 適合各類讀者：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。
我們的報告有哪些用途範例？
產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發和競爭情報。
報告範圍
- 歷史資料為 2021 年至 2024 年，基準年為 2025 年，預測期間為 2026 年至 2031 年。
- 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
- 競爭定位、策略、市場佔有率評估、貿易分析
- 細分市場和區域銷售成長及預測評估
- 公司簡介，包括策略、產品、財務狀況和主要發展動態。
目錄
第1章：執行摘要
- 腫瘤浸潤淋巴球療法（TIL療法）市場的定義與範圍
- 細胞療法的主要市場趨勢和發展趨勢
- 臨床開發和商業化概述
- 機率已調整的市場成長預測
- 戰略要點
第2章：腫瘤浸潤淋巴球療法（TIL療法）市場概述
- 市場定義與結構
- 腫瘤浸潤淋巴細胞療法（TIL療法）市場規模分析（2021-2025）
- 腫瘤浸潤淋巴球療法（TIL療法）市場規模預測（2026-2031年）
- 市場促進因素
- 在證明個人化細胞療法的臨床療效方面，已經取得了進展。
- 從黑色素瘤到固體癌的擴展
- 製造和自動化技術的進步
- 對先進治療方法的有利監管支持
- 市場限制因素
- 複雜的自製工藝
- 高昂的醫療成本和基礎設施需求
- 專業治療設施短缺
- 市場機遇
- 擴大應用範圍至子宮頸癌、肺癌及胃腸道癌症。
- 與查核點抑制劑合併使用
- 下一代TIL平台的開發
- 腫瘤浸潤淋巴細胞療法（TIL療法）市場細分
- 按癌症類型
- 黑色素瘤
- 子宮頸癌
- 非小細胞肺癌
- 卵巢癌
- 頭頸癌
- 其他
- 按治療類型
- 自體TIL療法
- 基因修飾的TIL療法
- 聯合TIL療法
- 按治療設定
- 住院治療
- 門診
- 最終用戶
- 大學醫院
- 癌症專科醫院
- 細胞治療中心
- 按癌症類型
第3章：流行病學與疾病負擔
- 腫瘤浸潤淋巴細胞療法可有效控制全球癌症負擔
- 惡性黑色素瘤的流行病學
- 子宮頸癌的流行病學
- 肺癌流行病學
- 對未來目標患者數量的分析
第4章：疾病分析及未滿足的需求
- 現有免疫療法的局限性
- 查核點抑制劑抗藥性固體癌的未滿足需求
- 對個人化細胞治療方法的需求
- 患者廣泛就醫的障礙
- 晚期疾病需要持續的治療效果
第5章：當前技術與治療狀況
- TIL療法的作用機制
- 腫瘤採集與細胞增生工作流程
- 淋巴球分離術和IL-2輔助性治療
- 製造和品管流程
- 自動化和封閉式系統生產
- 下一代基因編輯TIL方法
第6章 臨床開發與研發管線概述
- 臨床試驗趨勢
- 按開發階段分類的管道分佈
- 臨床前階段
- 第一階段
- 第二階段
- 第三階段
- 申請已提交/審核中
- 按癌症類型分類的管道分佈
- 按治療領域分類的管線分佈
- 臨床試驗設計基準測試
- 樣本大小分析
- 終點評估
- 參與者招募計劃
- 時期分析
- 成功率與失敗率分析
- 細胞治療計畫終止趨勢
- 監管指定和快速核准流程
第7章：管道資產基準分析
- 黑色素瘤TIL資產
- 子宮頸癌 TIL 資產
- 肺癌TIL資產
- 卵巢癌 TIL 資產
- 基因改造TIL程序
- 「First-in-Class」與「同類最佳」評價
- 新製造平台分析
第8章：成功機率與風險分析
- 臨床成功機率建模
- 相變機率分析
- 風險已調整的管道評估
- 流失率評估
- 主要風險因素
- 製造缺陷
- 患者合格限制
- 毒性管理面臨的挑戰
- 還款和獲取障礙
- 敏感度分析和情景分析
第9章：商業與市場動態
- 商業化現狀
- 預計發射時間表
- 機率加權收益預測
- 銷售高峰機會分析
- 定價和兌換趨勢
- 治療中心容量分析
- 關鍵資產的競爭定位
第10章 區域分析
- 北美洲
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東和非洲
第11章：公司簡介
- Bristol Myers Squibb
- Instil Bio, Inc.
- Obsidian Therapeutics, Inc.
- Turnstone Biologics Corp.
- Lyell Immunopharma, Inc.
- PACT Pharma, Inc.
- Lion TCR Pte Ltd
- Alaunos Therapeutics, Inc.
- Iovance Biotherapeutics, Inc.
- Merck & Co., Inc.
第12章：併購與投資趨勢
- 授權協議
- 聯合發展夥伴關係
- 併購
- 創業投資及公共資金籌措
- 對製造設施的投資
- 細胞治療領域的策略夥伴關係
第13章：未來展望與策略洞察
- 擴展到黑色素瘤以外的領域
- 自動化和製造規模化
- 與查核點抑制劑合併使用
- 同種異體和基因編輯TILs的創新
- 策略建議
第14章：調查方法與資料框架
- 數據來源
- 臨床試驗檢驗框架
- 管道納入標準
- 建立市場模型和預測方法
- 機率調整調查方法
- 局限性和假設
The Tumor-Infiltrating Lymphocyte (TIL) Therapy Market is set to reach USD 550.494 million in 2031, growing at a CAGR of 10.6 % from USD 332.51 million in 2026.
The global tumor infiltrating lymphocyte (TIL) therapy market is experiencing significant expansion as healthcare systems increasingly adopt advanced immunotherapy solutions for the treatment of solid tumors and refractory cancers. Tumor infiltrating lymphocyte therapy is a type of adoptive cell therapy that utilizes immune cells naturally present within a patient's tumor microenvironment. These lymphocytes are isolated from tumor tissue, expanded ex vivo, and reinfused into the patient to stimulate targeted anti-tumor immune responses. TIL therapy has emerged as a promising treatment approach for patients with advanced cancers who have limited response to conventional therapies and checkpoint inhibitors.
The increasing global burden of cancer remains one of the primary growth drivers for the market. Rising incidences of melanoma, cervical cancer, lung cancer, colorectal cancer, ovarian cancer, and head and neck cancers are increasing demand for innovative immunotherapy solutions capable of improving treatment outcomes. Conventional therapies such as chemotherapy and radiation therapy often face limitations related to systemic toxicity, tumor resistance, and disease recurrence. TIL therapies are increasingly being adopted because they offer personalized and targeted immune-mediated anti-cancer activity with the potential for durable clinical responses.
The growing adoption of personalized medicine and precision oncology is significantly supporting market expansion. TIL therapy utilizes patient-derived immune cells, enabling highly individualized treatment strategies tailored to the patient's tumor biology and immune profile. Precision medicine initiatives integrating genomic profiling, biomarker analysis, and molecular diagnostics are further strengthening the role of cellular immunotherapies in oncology treatment planning.
Technological advancements in cell expansion technologies, tumor profiling, gene editing, and cell manufacturing platforms are transforming the TIL therapy market. Automated manufacturing systems, improved lymphocyte isolation methods, and optimized cell culture technologies are enhancing production efficiency and scalability. Researchers are increasingly investigating genetically modified TILs, combination immunotherapy approaches, and next-generation cell engineering technologies to improve therapeutic efficacy and persistence.
The market is also benefiting from increasing pharmaceutical and biotechnology investment in immuno-oncology research and adoptive cell therapy development. Companies are expanding clinical trial programs focused on TIL therapies for solid tumors and combination treatment approaches involving checkpoint inhibitors, cytokine therapies, and targeted agents. Strategic collaborations between biotechnology firms, cancer research institutes, and healthcare providers are accelerating innovation in personalized immunotherapy solutions.
Growing regulatory support and increasing awareness regarding cellular immunotherapy are further contributing to market growth. Regulatory agencies are increasingly supporting development of advanced immunotherapies through accelerated approval pathways and orphan drug designations. Healthcare providers and oncology centers are also expanding investment in specialized cell therapy infrastructure and accredited treatment facilities to support broader clinical adoption.
North America currently dominates the tumor infiltrating lymphocyte therapy market due to advanced biotechnology infrastructure, strong oncology research capabilities, and significant investment in immunotherapy innovation. Europe also represents a substantial market supported by increasing precision medicine initiatives and expanding cancer research programs. Asia Pacific is expected to witness rapid growth due to rising healthcare expenditure, increasing cancer burden, and expanding biotechnology investment in countries such as China, Japan, South Korea, and India.
Despite strong growth prospects, the market faces challenges related to high treatment costs, manufacturing complexity, limited scalability, and therapy-related adverse events. However, ongoing advancements in automated cell manufacturing, genomic medicine, and combination immunotherapy strategies are expected to create substantial long-term growth opportunities for the tumor infiltrating lymphocyte therapy market.
Market Drivers
Increasing Prevalence of Solid Tumors
The growing global incidence of solid tumors is one of the major drivers of the tumor infiltrating lymphocyte therapy market. Rising cases of melanoma, cervical cancer, lung cancer, colorectal cancer, and ovarian cancer are increasing demand for advanced immunotherapy solutions capable of improving patient survival outcomes.
TIL therapies have demonstrated promising clinical effectiveness in patients with advanced and treatment-resistant cancers, particularly in melanoma and cervical cancer. Expanding clinical evidence supporting durable therapeutic responses is accelerating physician adoption and clinical research activity.
Growing Adoption of Personalized Immunotherapy
The increasing focus on personalized medicine and targeted oncology is significantly supporting market growth. TIL therapies are developed using patient-derived immune cells, enabling highly individualized treatment approaches tailored to tumor-specific immune responses.
Healthcare providers are increasingly adopting personalized immunotherapies to improve treatment precision, reduce recurrence risk, and enhance long-term therapeutic effectiveness.
Advancements in Cell Expansion and Manufacturing Technologies
Continuous innovation in cell isolation, lymphocyte expansion, automated manufacturing, and cell engineering technologies is positively influencing the market. Improved manufacturing platforms are enhancing scalability, reducing contamination risk, and improving production consistency.
Automated and closed-system manufacturing technologies are expected to reduce production timelines and improve broader accessibility of TIL therapies across healthcare systems.
Increasing Investment in Immuno-Oncology Research
Pharmaceutical companies, biotechnology firms, and research institutions are significantly increasing investment in TIL therapy clinical trials and immuno-oncology research. Researchers are evaluating TIL therapies across multiple solid tumor indications and combination treatment strategies.
Combination approaches involving checkpoint inhibitors, cytokine therapies, and targeted agents are demonstrating promising clinical potential and expanding future therapeutic opportunities.
Growing Regulatory Support for Cell Therapies
Regulatory agencies are increasingly supporting development of advanced cell therapies through accelerated review programs, orphan drug designations, and regenerative medicine frameworks.
Increasing regulatory approvals for adoptive cell therapies and expanding healthcare investment in oncology infrastructure are improving long-term market growth prospects.
Market Restraints
High Cost of TIL Therapy
One of the major restraints affecting the tumor infiltrating lymphocyte therapy market is the high cost associated with treatment and individualized manufacturing processes. TIL therapy involves tumor tissue extraction, lymphocyte isolation, cell expansion, and reinfusion procedures requiring specialized infrastructure and technical expertise.
High treatment expenses may limit patient accessibility and create reimbursement challenges, particularly in emerging healthcare markets.
Complex and Time-Intensive Manufacturing Process
TIL therapy production involves multiple complex steps including surgical tumor extraction, ex vivo lymphocyte expansion, quality control testing, and reinfusion. The manufacturing process can be lengthy and resource-intensive.
Coordinating individualized production workflows and maintaining consistent manufacturing quality may limit scalability and broader clinical adoption.
Therapy-Related Adverse Events
TIL therapies may be associated with adverse effects related to lymphodepleting chemotherapy, cytokine administration, and immune activation. Patients may experience cytokine-related toxicities, immune complications, and treatment-related side effects requiring specialized monitoring.
Management of adverse events often requires administration within accredited oncology centers equipped for intensive supportive care.
Limited Commercialization and Infrastructure Availability
TIL therapies currently remain available in limited healthcare centers with specialized cell therapy infrastructure and manufacturing capabilities. Limited treatment center availability may restrict patient access in certain regions.
Healthcare systems may require substantial investment in cell processing facilities, skilled personnel, and regulatory compliance systems to support broader adoption.
Technology and Segment Insights
The tumor infiltrating lymphocyte therapy market is segmented by therapy type, cancer indication, end-user, and geography. By therapy type, the market includes autologous TIL therapy, genetically modified TIL therapy, and combination TIL therapies. Autologous TIL therapy currently dominates the market because of its established clinical development and growing utilization in melanoma treatment.
Genetically modified TIL therapies are also witnessing increasing interest due to advancements in gene editing technologies and efforts to improve therapeutic persistence and anti-tumor activity.
Based on cancer indication, the market includes melanoma, cervical cancer, lung cancer, colorectal cancer, ovarian cancer, head and neck cancer, and others. Melanoma currently accounts for the largest market share due to strong clinical evidence supporting TIL therapy effectiveness in advanced melanoma patients.
Cervical cancer and lung cancer are also emerging application areas because of increasing clinical trial activity and growing interest in solid tumor immunotherapy approaches.
By end-user, the market includes hospitals, cancer treatment centers, academic and research institutions, and specialty oncology clinics. Hospitals and specialized cancer treatment centers currently account for a substantial market share due to the complex clinical management and infrastructure requirements associated with TIL therapy administration.
Academic and research institutions are also major contributors due to increasing involvement in immunotherapy clinical trials and translational oncology research.
Regionally, North America dominates the market due to advanced biotechnology ecosystems, strong oncology research infrastructure, and substantial healthcare investment in immunotherapy innovation. Europe continues to witness significant growth supported by increasing precision medicine initiatives and expanding oncology clinical research. Asia Pacific is expected to experience rapid expansion due to improving healthcare infrastructure, rising cancer burden, and increasing biotechnology investment.
Competitive and Strategic Outlook
The tumor infiltrating lymphocyte therapy market is highly competitive and characterized by the presence of biotechnology companies, immunotherapy developers, and oncology research organizations. Key market participants include Iovance Biotherapeutics, Inc., Achilles Therapeutics plc, Instil Bio, Inc., Obsidian Therapeutics, Inc., Turnstone Biologics Corp., Genocea Biosciences, Inc., BioNTech SE, Merck & Co., Inc., Bristol Myers Squibb Company, and F. Hoffmann-La Roche Ltd.
Leading companies are increasingly focusing on next-generation TIL therapies, automated manufacturing platforms, and combination immunotherapy approaches to strengthen market positioning. Investments in gene editing technologies, AI-driven biomarker discovery, and advanced cell engineering are accelerating across the industry.
Iovance Biotherapeutics continues to maintain a strong market position through clinical development of lifileucel and expansion of TIL manufacturing capabilities. Biotechnology firms are increasingly evaluating TIL therapies in combination with checkpoint inhibitors and targeted therapies to improve treatment efficacy in solid tumors.
Strategic collaborations between biotechnology companies, pharmaceutical manufacturers, and cancer research institutions are accelerating innovation in adoptive cell therapy development. Companies are also increasingly investing in decentralized manufacturing platforms and automated production systems to improve scalability and patient accessibility.
The market is witnessing growing focus on improving therapeutic durability, reducing manufacturing complexity, and expanding applications across multiple solid tumor indications. Companies capable of improving manufacturing efficiency, clinical outcomes, and treatment accessibility are expected to strengthen long-term market competitiveness.
Conclusion
The global tumor infiltrating lymphocyte therapy market is expected to witness strong growth due to increasing cancer prevalence, rising adoption of personalized immunotherapy, and continuous advancements in cellular therapy technologies.
TIL therapy is transforming solid tumor treatment by enabling personalized and targeted immune-mediated anti-cancer responses using patient-derived lymphocytes. Growing investment in immuno-oncology research, genomic medicine, and advanced cell manufacturing technologies is further strengthening market expansion.
Technological advancements in automated cell processing, gene editing, biomarker analysis, and combination immunotherapy strategies are significantly improving therapeutic innovation and clinical potential. However, challenges related to high treatment costs, manufacturing complexity, therapy-related adverse events, and limited treatment infrastructure continue to affect broader market adoption.
Despite these restraints, ongoing innovation in adoptive cell therapy, personalized oncology, and precision immunotherapy is expected to create substantial long-term growth opportunities for the tumor infiltrating lymphocyte therapy market.
Key Benefits of this Report
- Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
- Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
- Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
- Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
- Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.
What Businesses Use Our Reports For
Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.
Report Coverage
- Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
- Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
- Competitive positioning, strategies, and market share evaluation, and trade analysis
- Revenue growth and forecast assessment across segments and regions
- Company profiling including strategies, products, financials, and key developments
TABLE OF CONTENTS
1. Executive Summary
- 1.1 Tumor-Infiltrating Lymphocyte Therapy Market Definition and Scope
- 1.2 Key Market Insights and Cell Therapy Adoption Trends
- 1.3 Clinical Development and Commercialization Snapshot
- 1.4 Probability-Adjusted Market Growth Outlook
- 1.5 Strategic Takeaways
2. Tumor-Infiltrating Lymphocyte Therapy Market Overview
- 2.1 Market Definition and Structure
- 2.2 Tumor-Infiltrating Lymphocyte Therapy Market Size Analysis 2021-2025
- 2.3 Tumor-Infiltrating Lymphocyte Therapy Market Size Forecast 2026-2031
- 2.4 Market Drivers
- 2.4.1 Increasing Clinical Validation of Personalized Cell Therapies
- 2.4.2 Expansion Beyond Melanoma into Solid Tumors
- 2.4.3 Advancements in Manufacturing and Automation
- 2.4.4 Favorable Regulatory Support for Advanced Therapies
- 2.5 Market Restraints
- 2.5.1 Complex Autologous Manufacturing Processes
- 2.5.2 High Treatment Cost and Infrastructure Requirements
- 2.5.3 Limited Specialized Treatment Centers
- 2.6 Market Opportunities
- 2.6.1 Expansion into Cervical, Lung, and Gastrointestinal Cancers
- 2.6.2 Combination with Checkpoint Inhibitors
- 2.6.3 Development of Next-Generation TIL Platforms
- 2.7 Tumor-Infiltrating Lymphocyte Therapy Market Segmentation
- 2.7.1 By Cancer Type
- 2.7.1.1 Melanoma
- 2.7.1.2 Cervical Cancer
- 2.7.1.3 Non-Small Cell Lung Cancer
- 2.7.1.4 Ovarian Cancer
- 2.7.1.5 Head and Neck Cancer
- 2.7.1.6 Others
- 2.7.2 By Therapy Type
- 2.7.2.1 Autologous TIL Therapy
- 2.7.2.2 Genetically Modified TIL Therapy
- 2.7.2.3 Combination TIL Therapy
- 2.7.3 By Treatment Setting
- 2.7.3.1 Inpatient
- 2.7.3.2 Outpatient
- 2.7.4 By End User
- 2.7.4.1 Academic Medical Centers
- 2.7.4.2 Specialty Cancer Hospitals
- 2.7.4.3 Cell Therapy Centers
- 2.7.1 By Cancer Type
3. Epidemiology and Disease Burden
- 3.1 Global Cancer Burden Addressable by TIL Therapy
- 3.2 Melanoma Epidemiology
- 3.3 Cervical Cancer Epidemiology
- 3.4 Lung Cancer Epidemiology
- 3.5 Future Eligible Patient Population Analysis
4. Disease and Unmet Need Analysis
- 4.1 Limitations of Existing Immunotherapies
- 4.2 Unmet Need in Checkpoint-Refractory Solid Tumors
- 4.3 Need for Personalized Cell Therapy Approaches
- 4.4 Barriers to Broad Patient Access
- 4.5 Demand for Durable Responses in Advanced Disease
5. Technology and Treatment Landscape
- 5.1 TIL Therapy Mechanism of Action
- 5.2 Tumor Harvest and Cell Expansion Workflow
- 5.3 Lymphodepletion and IL-2 Support Regimens
- 5.4 Manufacturing and Quality Control Processes
- 5.5 Automation and Closed-System Production
- 5.6 Next-Generation Gene-Edited TIL Approaches
6. Clinical Development and Pipeline Landscape
- 6.1 Clinical Trial Activity
- 6.2 Pipeline Distribution by Development Phase
- 6.2.1 Preclinical
- 6.2.2 Phase I
- 6.2.3 Phase II
- 6.2.4 Phase III
- 6.2.5 Filed and Under Regulatory Review
- 6.3 Pipeline Distribution by Cancer Type
- 6.4 Pipeline Distribution by Therapy Type
- 6.5 Clinical Trial Design Benchmarking
- 6.5.1 Sample Size Analysis
- 6.5.2 Endpoint Assessment
- 6.5.3 Recruitment Timelines
- 6.5.4 Duration Analysis
- 6.6 Success and Failure Rate Analysis
- 6.7 Attrition Trends in Cell Therapy Programs
- 6.8 Regulatory Designations and Accelerated Pathways
7. Pipeline Asset Benchmarking
- 7.1 Melanoma TIL Assets
- 7.2 Cervical Cancer TIL Assets
- 7.3 Lung Cancer TIL Assets
- 7.4 Ovarian Cancer TIL Assets
- 7.5 Gene-Modified TIL Programs
- 7.6 First-in-Class vs Best-in-Class Assessment
- 7.7 Novel Manufacturing Platform Analysis
8. Probability of Success and Risk Analysis
- 8.1 Clinical Success Probability Modeling
- 8.2 Phase Transition Probability Analysis
- 8.3 Risk-Adjusted Pipeline Valuation
- 8.4 Attrition Rate Assessment
- 8.5 Key Risk Factors
- 8.5.1 Manufacturing Failures
- 8.5.2 Patient Eligibility Constraints
- 8.5.3 Toxicity Management Challenges
- 8.5.4 Reimbursement and Access Barriers
- 8.6 Sensitivity and Scenario Analysis
9. Commercial and Market Dynamics
- 9.1 Commercialization Landscape
- 9.2 Launch Timeline Forecasting
- 9.3 Probability-Weighted Revenue Forecasts
- 9.4 Peak Sales Opportunity Analysis
- 9.5 Pricing and Reimbursement Trends
- 9.6 Treatment Center Capacity Analysis
- 9.7 Competitive Positioning of Leading Assets
10. Geographic Analysis
- 10.1 North America
- 10.2 Europe
- 10.3 Asia-Pacific
- 10.4 Latin America
- 10.5 Middle East and Africa
11. Company Profiles
- 11.1 Bristol Myers Squibb
- 11.1.1 Overview
- 11.1.2 Financials
- 11.1.3 TIL Therapy Portfolio
- 11.1.4 Manufacturing Capabilities
- 11.1.5 Recent Developments
- 11.2 Instil Bio, Inc.
- 11.3 Obsidian Therapeutics, Inc.
- 11.4 Turnstone Biologics Corp.
- 11.5 Lyell Immunopharma, Inc.
- 11.6 PACT Pharma, Inc.
- 11.7 Lion TCR Pte Ltd
- 11.8 Alaunos Therapeutics, Inc.
- 11.9 Iovance Biotherapeutics, Inc.
- 11.10 Merck & Co., Inc.
12. Deals and Investment Landscape
- 12.1 Licensing Agreements
- 12.2 Co-Development Partnerships
- 12.3 Mergers and Acquisitions
- 12.4 Venture Capital and Public Financing
- 12.5 Manufacturing Facility Investments
- 12.6 Strategic Cell Therapy Collaborations
13. Future Outlook and Strategic Insights
- 13.1 Expansion Beyond Melanoma
- 13.2 Automation and Manufacturing Scale-Up
- 13.3 Combination with Checkpoint Inhibitors
- 13.4 Allogeneic and Gene-Edited TIL Innovations
- 13.5 Strategic Recommendations
14. Methodology and Data Framework
- 14.1 Data Sources
- 14.2 Clinical Trial Validation Framework
- 14.3 Pipeline Inclusion Criteria
- 14.4 Market Modeling and Forecasting Approach
- 14.5 Probability Adjustment Methodology
- 14.6 Limitations and Assumptionss
